



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

**Public Declaration of Interests and Confidentiality Undertaking of
European Medicines Agency (EMA),
Scientific Committee members and experts**

Public declaration of interests

I, Bozenna Dembowska-Baginska

Organisation/Company: The Children's Memorial Health Institute

Country: Poland

do hereby declare on my honour that, to the best of my knowledge, the only direct or indirect interests I have in the pharmaceutical industry are those listed below:

2.1 Employment

No interest declared

2.2 Consultancy

No interest declared

2.3 Strategic advisory role

No interest declared

2.4 Financial interests

No interest declared

2.5 Principal investigator

No interest declared

2.6 Investigator

Period	Company	Products	Therapeutic Indication
07/2007-06/2010	Wyeth	Temsirolimus	Pediatric patients with

			relapsed/refractory solid tumors- phase I/II
04/2011-05/2012	Purue Pharma	Oxycodone	Malignant pain in children (no patients recruited)
09/2010-08/2019	Roche	Bevacizumab	Metastatic soft tissue sarcoma in children
02/2011-03/2014	Pierre Fabre	Propranolol	Infantile hemangioma
01/2015-01/2016	Guerbet	DOTAREM	imaging contrast agent for use with magnetic resonance
07/2016-07/2017	Pierre Fabre	Propranolol	Infantile hemangioma
11/2017-(current)	BMS	Nivolumab, Ipilimumab	High Grade Primary CNS Malignancies
10/2018-02/2019	Merck Sharp & Dohme Corp (MSD)	Pembrolizumab	Melanoma
06/2015-(current)	TEVA	Lipegfilgrastim	Neutropenia in children undergoing anticancer chemotehrapy
06/2016-03/2017	TEVA	TBO Filgrastim	Neutropenia in children undergoing myelosuppressive chemotherapy
02/2016-02/2017	MSD	Fosaprepitant	Prevention of nausea and vomitting in children undergoing emetogenic chemotherapy
01/2019-(current)	GUERBET	GDX-44-007	imaging contrast agent used with magnetic resonance in children
10/2019-(current)	MSD	Fosaprepitant	Prevention of nasuea and vomitting in children undergoing emetogenic chemotherapy (phase 4)

2.7 Grant / Funding to organisation /institution

No interest declared

2.8 Close family member interest

No interest declared

2.9 Any other interests or facts

No interest declared

CONFIDENTIALITY UNDERTAKING

In view of the following definitions:

"EMA Activities" encompass any meeting (including meeting preparation and follow-up, associated discussion or any other related activity) of the European Medicines Agency's Management Board, Committees, Working Parties, Expert Groups, or any other such meeting; work as an expert on assessments; work as an expert on guidance

development.

"Confidential Information" means all information, facts, data and any other matters of which I acquire knowledge, either directly or indirectly, as a result of my EMA Activities.

"Confidential Documents" mean all drafts, preparatory information, documents and any other material, together with any information contained therein, to which I have access, either directly or indirectly, as a result of my participation in EMA Activities. Furthermore, any records or notes made by me relating to Confidential Information or Confidential Documents shall be treated as Confidential Documents.

I understand that I may be invited to participate either directly or indirectly in certain EMA activities and hereby undertake:

- To treat all Confidential Information and Confidential Documents under conditions of strict confidentiality.
- Not to disclose (or authorise any other person to disclose) in any way to any third party any Confidential Information or Confidential Document.
- Not to use (or authorise any other person to use) any Confidential Information or Confidential Document other than for the purposes of my work in connection with EMA activities.
- To dispose of Confidential Documents as confidential material as soon as I have no further use for them.

This undertaking shall not be limited in time, but shall not apply to any document or information that I can reasonably prove was known to me before the date of this undertaking or which becomes public knowledge other than as a result of a breach of any of the above undertakings.

I confirm the information declared on this form is accurate to the best of my knowledge and I acknowledge that my information will be stored electronically and published on the EMA website.

Full Name:	Bozenna Dembowska-Baginska
Date:	2019-10-09

For Definitions of activities etc, refer to Policy on Handling of Conflicts of Interest / Electronic DOI template